Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.14.5482 on March 10 2008

Journal of Clinical Oncology, Vol 26, No 10 (April 1), 2008: pp. 1603-1610
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tabernero, J.
Right arrow Articles by Baselga, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tabernero, J.
Right arrow Articles by Baselga, J.
Related Articles
Right arrowRelated Articles
Right arrowRelated Editorial
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard Burris, Ian Judson, Katharine Hazell, Erika Martinelli, Santiago Ramon y Cajal, Suzanne Jones, Laura Vidal, Nicholas Shand, Teresa Macarulla, Francisco Javier Ramos, Sasa Dimitrijevic, Ulrike Zoellner, Pui Tang, Michael Stumm, Heidi A. Lane, David Lebwohl, José Baselga

From the Medical Oncology and Pathology Departments, Vall d’Hebron University Hospital, Barcelona, Spain; Medical Oncology Department, Sarah Cannon Cancer Center, Nashville, TN; Medical Oncology Department, Royal Marsden Hospital, London, United Kingdom; Novartis Oncology, Basel, Switzerland; and Novartis Oncology, Florham Park, NJ

Corresponding author: José Baselga, MD, Medical Oncology Department, Vall d’Hebron University Hospital, P. Vall d’Hebron, 119-129, 08035, Barcelona, Spain; e-mail: jbaselga{at}vhebron.net

Purpose Everolimus is a selective mammalian target of rapamycin (mTOR) inhibitor with promising anticancer activity. In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I study in patients with advanced solid tumors.

Patients and Methods Fifty-five patients were treated with everolimus in cohorts of 20, 50, and 70 mg weekly or 5 and 10 mg daily. Dose escalation depended on dose limiting toxicity (DLT) rate during the first 4-week period. Pre- and on-treatment steady-state tumor and skin biopsies were evaluated for total and phosphorylated (p) protein S6 kinase 1, eukaryotic initiation factor 4E (elF-4E) binding protein 1 (4E-BP1), eukaryotic initiation factor 4G (eIF-4G), AKT, and Ki-67 expression. Plasma trough levels of everolimus were determined on a weekly basis before dosing during the first 4 weeks.

Results We observed a dose- and schedule-dependent inhibition of the mTOR pathway with a near complete inhibition of pS6 and peIF-4G at 10 mg/d and ≥ 50 mg/wk. In addition, pAKT was upregulated in 50% of the treated tumors. In the daily schedule, there was a correlation between everolimus plasma trough concentrations and inhibition of peIF4G and p4E-BP1. There was good concordance of mTOR pathway inhibition between skin and tumor. Clinical benefit was observed in four patients including one patient with advanced colorectal cancer achieving a partial response. DLTs occurred in five patients: one patient at 10 mg/d (grade 3 stomatitis) and four patients at 70 mg/wk (two with grade 3 stomatitis, one with grade 3 neutropenia, and one with grade 3 hyperglycemia).

Conclusion Everolimus achieved mTOR signaling inhibition at doses below the DLT. A dosage of 10 mg/d or 50 mg/wk is recommended for further development.

Submitted September 20, 2007; accepted November 16, 2007.

Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005; and at the 13th European Cancer Conference, Paris, France, October 30 to November 3, 2005.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Articles

  • Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
    Anne O'Donnell, Sandrine Faivre, Howard A. Burris, III, Daniel Rea, Vassiliki Papadimitrakopoulou, Nicholas Shand, Heidi A. Lane, Katharine Hazell, Ulrike Zoellner, John M. Kovarik, Cathryn Brock, Suzanne Jones, Eric Raymond, and Ian Judson
    JCO 2008 26: 1588-1595 [Abstract] [Full Text]
  • Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
    Chiaki Tanaka, Terence O’Reilly, John M. Kovarik, Nicholas Shand, Katharine Hazell, Ian Judson, Eric Raymond, Sabine Zumstein-Mecker, Christine Stephan, Anne Boulay, Marc Hattenberger, George Thomas, and Heidi A. Lane
    JCO 2008 26: 1596-1602 [Abstract] [Full Text]

Related Editorial

  • Dose Selection in Phase I Studies: Why We Should Always Go for the Top
    Stefan Sleijfer and Erik Wiemer
    JCO 2008 26: 1576-1578 [Full Text]


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. C. Manara, G. Nicoletti, D. Zambelli, S. Ventura, C. Guerzoni, L. Landuzzi, P.-L. Lollini, S.-M. Maira, C. Garcia-Echeverria, M. Mercuri, et al.
NVP-BEZ235 as a New Therapeutic Option for Sarcomas
Clin. Cancer Res., January 15, 2010; 16(2): 530 - 540.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. C. Yao, C. Lombard-Bohas, E. Baudin, L. K. Kvols, P. Rougier, P. Ruszniewski, S. Hoosen, J. St. Peter, T. Haas, D. Lebwohl, et al.
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
J. Clin. Oncol., January 1, 2010; 28(1): 69 - 76.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
I. Okamoto, T. Doi, A. Ohtsu, M. Miyazaki, A. Tsuya, K. Kurei, K. Kobayashi, and K. Nakagawa
Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
Jpn. J. Clin. Oncol., January 1, 2010; 40(1): 17 - 23.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
C. Sessa, D. Tosi, L. Vigano, J. Albanell, D. Hess, M. Maur, S. Cresta, A. Locatelli, R. Angst, F. Rojo, et al.
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
Ann. Onc., November 9, 2009; (2009) mdp504v1.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. T. Kurmasheva, L. Dudkin, C. Billups, L. V. Debelenko, C. L. Morton, and P. J. Houghton
The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma
Cancer Res., October 1, 2009; 69(19): 7662 - 7671.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. L. Ellard, M. Clemons, K. A. Gelmon, B. Norris, H. Kennecke, S. Chia, K. Pritchard, A. Eisen, T. Vandenberg, M. Taylor, et al.
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
J. Clin. Oncol., September 20, 2009; 27(27): 4536 - 4541.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone
Target-based therapies in breast cancer: current status and future perspectives
Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Baselga, V. Semiglazov, P. van Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, et al.
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
J. Clin. Oncol., June 1, 2009; 27(16): 2630 - 2637.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Meric-Bernstam and A. M. Gonzalez-Angulo
Targeting the mTOR Signaling Network for Cancer Therapy
J. Clin. Oncol., May 1, 2009; 27(13): 2278 - 2287.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Breuleux, M. Klopfenstein, C. Stephan, C. A. Doughty, L. Barys, S.-M. Maira, D. Kwiatkowski, and H. A. Lane
Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
Mol. Cancer Ther., April 1, 2009; 8(4): 742 - 753.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Ogino, K. Nosho, G. J. Kirkner, K. Shima, N. Irahara, S. Kure, A. T. Chan, J. A. Engelman, P. Kraft, L. C. Cantley, et al.
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
J. Clin. Oncol., March 20, 2009; 27(9): 1477 - 1484.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. M. Wolpin, A. F. Hezel, T. Abrams, L. S. Blaszkowsky, J. A. Meyerhardt, J. A. Chan, P. C. Enzinger, B. Allen, J. W. Clark, D. P. Ryan, et al.
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
J. Clin. Oncol., January 10, 2009; 27(2): 193 - 198.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
P. A. Dennis
Rapamycin for Chemoprevention of Upper Aerodigestive Tract Cancers
Cancer Prevention Research, January 1, 2009; 2(1): 7 - 9.
[Full Text] [PDF]


Home page
Cancer Res.Home page
V. Serra, B. Markman, M. Scaltriti, P. J.A. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, et al.
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Cancer Res., October 1, 2008; 68(19): 8022 - 8030.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. K. Neklesa and R. W. Davis
Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex
PNAS, September 30, 2008; 105(39): 15166 - 15171.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Wang, P. Yue, Y. A. Kim, H. Fu, F. R. Khuri, and S.-Y. Sun
Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation
Cancer Res., September 15, 2008; 68(18): 7409 - 7418.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
I. E. Haines
Dose Selection in Phase I Studies: Why We Should Always Go for the Most Effective
J. Clin. Oncol., July 20, 2008; 26(21): 3650 - 3652.
[Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
J. R. Hecht
Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice
Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S15 - S21.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Sleijfer and E. Wiemer
Dose Selection in Phase I Studies: Why We Should Always Go for the Top
J. Clin. Oncol., April 1, 2008; 26(10): 1576 - 1578.
[Full Text] [PDF]


Home page
JCOHome page
C. Tanaka, T. O'Reilly, J. M. Kovarik, N. Shand, K. Hazell, I. Judson, E. Raymond, S. Zumstein-Mecker, C. Stephan, A. Boulay, et al.
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
J. Clin. Oncol., April 1, 2008; 26(10): 1596 - 1602.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online